Phenanthroline

Phenanthroline

SCHEMBL343516

Cl[Cu]Cl.c1cnc2c(c1)ccc1cccnc12

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 5/20 0.80
CCR8 P51685 5/20 0.80
LMNA P02545 4/20 0.80
CCR5 P51681 3/20 0.80
KDM4E B2RXH2 3/20 0.80
MMP2 P08253 2/20 0.80
TSHR P16473 2/20 0.80
MAPT P10636 2/20 0.80
HTT P42858 2/20 0.80
SMN1; SMN2 Q16637 2/20 0.80
TDP1 Q9NUW8 2/20 0.80
GMNN O75496 1/20 0.80
TP53 P04637 1/20 0.80
HSP90AA1 P07900 1/20 0.80
CYP3A4 P08684 1/20 0.80
CYP2D6 P10635 1/20 0.80
MMP9 P14780 1/20 0.80
ALOX15 P16050 1/20 0.80
NFKB1 P19838 1/20 0.80
MMP8 P22894 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenanthroline SCHEMBL30851477 1.00 CCR1 (0.80) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL29354015 0.89 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL29367277 0.89 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL8312 0.89 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL8845760 0.89 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL2813173 0.87 CCR1 (0.84) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL30945289 0.87 CCR1 (0.84) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL22982126 0.87 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL21044608 0.87 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL3812011 0.87 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747238-A1 PROCESS FOR PREPARING INTERMEDIATES OF SARTAN ACTIVE COMPOUNDS Sanofi (FR) 2026-05-27 EP claimed
WO-2025021696-A1 PROCESS FOR PREPARING INTERMEDIATES OF SARTAN ACTIVE COMPOUNDS SANOFI (FR) 2025-01-30 WO claimed
US-9611337-B2 Chain transfer agent, photosensitive composition, cured product of photosensitive composition, and method for curing photosensitive composition AUTONETWORKS TECHNOLOGIES, LTD. (JP) 2017-04-04 US claimed
US-20240360344-A1 CHEMICAL-RESISTANT, REACTIVE, PRESSURE-SENSITIVE ADHESIVE TAPE TESA SE (DE) 2024-10-31 US disclosed
WO-2024190525-A1 COLORED CURABLE RESIN COMPOSITION, OPTICAL FILTER, AND SOLID-STATE IMAGING ELEMENT 住友化学株式会社 2024-09-19 WO disclosed
US-12049465-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PFIZER INC. (US) 2024-07-30 US disclosed
WO-2024097736-A1 PROCESSES FOR PREPARING AZOLOPYRIMIDINE COMPOUNDS ARCUS BIOSCIENCES, INC. (US) 2024-05-10 WO disclosed
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-05-11 US disclosed
US-20230002386-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-01-05 US disclosed
US-11472805-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PFIZER, INC. (US) 2022-10-18 US disclosed
EP-3766885-B1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER (US) 2022-05-25 EP disclosed
US-9090796-B2 Organic-inorganic composite materials containing triazine rings and electrical devices using the same HITACHI, LTD. (JP) 2015-07-28 US disclosed
US-20130338327-A1 CHAIN TRANSFER AGENT, PHOTOSENSITIVE COMPOSITION, CURED PRODUCT OF PHOTOSENSITIVE COMPOSITION, AND METHOD FOR CURING PHOTOSENSITIVE COMPOSITION AUTONETWORKS TECHNOLOGIES, LTD. (JP) 2013-12-19 US disclosed
EP-2669299-A1 CHAIN TRANSFER AGENT, PHOTOSENSITIVE COMPOSITION, CURED PRODUCT OF PHOTOSENSITIVE COMPOSITION, AND METHOD FOR CURING PHOTOSENSITIVE COMPOSITION AutoNetworks Technologies, Ltd. (JP) 2013-12-04 EP disclosed
EP-2597114-A1 Organic-inorganic composite materials containing triazine rings and electrical devices using the same Hitachi Ltd. (JP) 2013-05-29 EP disclosed
US-20130131248-A1 ORGANIC-INORGANIC COMPOSITE MATERIALS CONTAINING TRIAZINE RINGS AND ELECTRICAL DEVICES USING THE SAME HITACHI, LTD. (JP) 2013-05-23 US disclosed
US-20120016152-A1 Process for the preparation of 4`-haloalkylbiphenyl-2-carboxylic acids SALTIGO GMBH (DE) 2012-01-19 US disclosed
US-7910272-B2 Dye-containing photosensitive composition, color filter using the same, and production method thereof FUJIFILM CORPORATION (JP) 2011-03-22 US disclosed
US-20070190435-A1 Dye-containing photosensitive composition, color filter using the same, and production method thereof FUJIFILM CORPORATION (JP) 2007-08-16 US disclosed
US-20040185372-A1 Dye-containing curable composition, color filter, and process of preparing color filter FUJI PHOTO FILM CO., LTD. 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049465-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PDE3B, PDE3A, PDE5A CCR1 2143/4885CCR8 3136/4885LMNA 1280/4885
US-20120016152-A1 Process for the preparation of 4`-haloalkylbiphenyl-2-carboxylic acids CYP4B1, HACL2, UGT1A4 CCR1 1938/4885CCR8 2653/4885LMNA 3085/4885
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE5A CCR1 2143/4885CCR8 3136/4885LMNA 1280/4885
US-11472805-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PDE3B, PDE3A, PDE5A CCR1 2143/4885CCR8 3136/4885LMNA 1280/4885
US-20230002386-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE5A CCR1 2143/4885CCR8 3136/4885LMNA 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.